<DOC>
	<DOCNO>NCT01983124</DOCNO>
	<brief_summary>The purpose study evaluate activity Vemurafenib combination Fotemustine Patients unresectable Stage IV melanoma harbor V600 BRAF mutation recur treatment Vemurafenib . In addition feasibility safety profile prolong treatment drug combination assess .</brief_summary>
	<brief_title>Vemurafenib + Fotemustine Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While Vemurafenib</brief_title>
	<detailed_description>Patients treat Fotemustine 100 mg/m2 q21 + Vemurafenib . Vemurafenib administer continuous oral dose 960 mg twice daily dose administered time disease progression Vemurafenib previous treatment ( 720 480 mg ) .Treatment continue progression unacceptable toxicity . The Progression-free survival assess primary endpoint , outcome ( i.e. , incidence grade III-IV toxicity , Disease Control Rate , Overall Survival ) consider secondary endpoint .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Fotemustine</mesh_term>
	<criteria>Histologically confirm melanoma harbor V600 mutation Unresectable Stage IV melanoma At least 18 age Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 In progression treatment Vemurafenib At least 2 week since last radiotherapy treatment Life expectancy &gt; 12 week Clinical laboratory value screen define follow : lactate dehydrogenase ( LDH ) &lt; 2.0 x upper limit normal ( ULN ) , Hemoglobin &gt; 9 g/dL , Absolute neutrophil count 1500/mm3 , Platelet count &gt; 100,000/mm3 , Creatinine &lt; 1.5 mg/dL ( NOTE : If creatinine &gt; 1.5 mg/dL , subject eligible creatinine clearance &gt; 60 mL/min use CockgroftGault equation ) , Total bilirubin &lt; 1.5 x ULN , Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase ( ALP ) &lt; 2.5 x ULN Negative serum pregnancy test within 7 day prior commencement dose premenopausal woman . Women nonchildbearing potential may include either surgically sterile postmenopausal ≥ 1 year Fertile men woman must use effective method contraception Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule Ability understand willingness sign write informed consent document Female subject pregnant nursing Female subject childbearing potential male use willing use two form effective contraception Any follow within 6 month prior randomization : myocardial infarction , severe/unstable angina , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism , hypertension adequately control current medication Concurrent administration anticancer therapy ( e.g . chemotherapy , target therapy , experimental drug , etc ) administer study Known hypersensitivity Vemurafenib another BRAF inhibitor History congenital long QT syndrome , history presence clinically significant ventricular atrial dysrhythmias ≥ Grade 2 ( NCI Common Toxicity Criteria Adverse Effects ( CTCAE ) Version 4.0 Corrected QT ( QTc ) interval ≥ 500 msec baseline Uncontrolled medical illness ( infection require treatment intravenous ( IV ) antibiotic ) Has surgery within 2 week ( 1 week minor surgery , eg , procedure require local anesthetic ) prior first dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Advanced Melanoma</keyword>
</DOC>